Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Basic): 2015-2024

Historic EPS (Basic) for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$0.81.

  • Seres Therapeutics' EPS (Basic) fell 91.92% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.30, marking a year-over-year increase of 965.36%. This contributed to the annual value of -$0.81 for FY2024, which is 45.64% up from last year.
  • Seres Therapeutics' EPS (Basic) amounted to -$0.81 in FY2024, which was up 45.64% from -$1.49 recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' EPS (Basic) ranged from a high of -$0.72 in FY2021 and a low of -$2.31 during FY2022.
  • Moreover, its 3-year median value for EPS (Basic) was -$1.49 (2023), whereas its average is -$1.54.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 220.83% in 2022, then spiked by 45.64% in 2024.
  • Over the past 5 years, Seres Therapeutics' EPS (Basic) (Yearly) stood at -$1.12 in 2020, then spiked by 35.71% to -$0.72 in 2021, then plummeted by 220.83% to -$2.31 in 2022, then surged by 35.50% to -$1.49 in 2023, then surged by 45.64% to -$0.81 in 2024.